Fortrea disputes ACELYRIN claims on HS and PsA trial conduct; stands by data integrity

Fortrea Holdings Inc.

Fortrea objects to ACELYRIN's implication that its conduct of the Hidradenitis Suppurativa trial impacted outcomes.
Disputes accuracy of statements about testing processes and who uncovered the third-party programming error in Psoriatic Arthritis trial.
Sequencing issue isolated to two arms of the PsA trial, unrelated to the HS trial; no patient safety risk per ACELYRIN.
Third-party programmer not endpoint Clinical (affiliated with Fortrea); cannot be named due to contractual commitments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.